Freestone Grove Partners LP Nurix Therapeutics, Inc. Transaction History
Freestone Grove Partners LP
- $8.16 Trillion
- Q4 2024
A detailed history of Freestone Grove Partners LP transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Freestone Grove Partners LP holds 16,724 shares of NRIX stock, worth $290,161. This represents 0.0% of its overall portfolio holdings.
Number of Shares
16,724Holding current value
$290,161% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding NRIX
# of Institutions
185Shares Held
70.6MCall Options Held
318KPut Options Held
42.4K-
Black Rock Inc. New York, NY6.82MShares$118 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.35MShares$75.4 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.19MShares$72.7 Million6.18% of portfolio
-
Baker Bros. Advisors LP New York, NY3.88MShares$67.4 Million0.81% of portfolio
-
Wellington Management Group LLP Boston, MA3.59MShares$62.2 Million0.01% of portfolio
About Nurix Therapeutics, Inc.
- Ticker NRIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 47,147,800
- Market Cap $818M
- Description
- Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...